Literature DB >> 22173654

Eye symptoms in relatives of patients with primary adult-onset dystonia.

Giovanni Defazio1, Giovanni Abbruzzese, Maria Stella Aniello, Roberta Di Fede, Marcello Esposito, Giovanni Fabbrini, Paolo Girlanda, Rocco Liguori, Lucio Marinelli, Davide Martino, Francesca Morgante, Lucio Santoro, Michele Tinazzi, Alfredo Berardelli.   

Abstract

METHODS: Using a validated questionnaire, we screened eye symptoms (burning sensation, grittiness, dry eye) in 333 first-degree relatives of 140 probands with different forms of primary adult-onset dystonia, 208 healthy subjects, and 293 patients with primary blepharospasm.
RESULTS: The rate of eye symptoms was similar in the relatives of focal dystonia patients and in healthy subjects (adjusted HR, 1.1; 95% CI, 0.7-1.7; P = .69), thus suggesting a common origin of eye symptoms in both groups. A higher rate was observed in blepharospasm patients (adjusted HR, 2; 95% CI, 1.4-2.9; P < .0001). Relatives of focal dystonia patients who developed blepharospasm were more likely to have preceding eye symptoms than were relatives who developed focal dystonia other than blepharospasm (BSP) or relatives who did not develop dystonia.
CONCLUSIONS: Eye symptoms reported by relatives of patients with focal dystonia probably result from eye diseases and are not part of the clinical spectrum of blepharospasm.
Copyright © 2011 Movement Disorder Society.

Entities:  

Mesh:

Year:  2011        PMID: 22173654     DOI: 10.1002/mds.24026

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  8 in total

Review 1.  Blepharospasm 40 years later.

Authors:  Giovanni Defazio; Mark Hallett; Hyder A Jinnah; Antonella Conte; Alfredo Berardelli
Journal:  Mov Disord       Date:  2017-02-10       Impact factor: 10.338

2.  Motor and non-motor symptoms in blepharospasm: clinical and pathophysiological implications.

Authors:  Gina Ferrazzano; Isabella Berardelli; Antonella Conte; Viola Baione; Cristina Concolato; Daniele Belvisi; Giovanni Fabbrini; Giovanni Defazio; Alfredo Berardelli
Journal:  J Neurol       Date:  2019-07-29       Impact factor: 4.849

3.  Development and validation of a clinical guideline for diagnosing blepharospasm.

Authors:  Giovanni Defazio; Mark Hallett; Hyder A Jinnah; Alfredo Berardelli
Journal:  Neurology       Date:  2013-06-14       Impact factor: 9.910

4.  Epidemiology of benign essential blepharospasm: A nationwide population-based retrospective study in Taiwan.

Authors:  Yng Sun; Pei-Jhen Tsai; Chin-Liang Chu; Wei-Chun Huang; Youn-Shen Bee
Journal:  PLoS One       Date:  2018-12-26       Impact factor: 3.240

5.  Ocular surface status in patients with hemifacial spasm under long-lasting treatment with botulinum A toxin: A comparative fellow eye study.

Authors:  Marco Pellegrini; Costantino Schiavi; Leonardo Taroni; Stefano Sebastiani; Federico Bernabei; Matilde Roda; Fabiana Moscardelli; Giuseppe Giannaccare
Journal:  Indian J Ophthalmol       Date:  2019-09       Impact factor: 1.848

6.  Clinical Features and Evolution of Blepharospasm: A Multicenter International Cohort and Systematic Literature Review.

Authors:  Laura M Scorr; Hyun Joo Cho; Gamze Kilic-Berkmen; J Lucas McKay; Mark Hallett; Christine Klein; Tobias Baumer; Brian D Berman; Jeanne S Feuerstein; Joel S Perlmutter; Alfredo Berardelli; Gina Ferrazzano; Aparna Wagle-Shukla; Irene A Malaty; Joseph Jankovic; Steven T Bellows; Richard L Barbano; Marie Vidailhet; Emmanuel Roze; Cecilia Bonnet; Abhimanyu Mahajan; Mark S LeDoux; Victor S C Fung; Florence C F Chang; Giovanni Defazio; Tomaso Ercoli; Stewart Factor; Ted Wojno; H A Jinnah
Journal:  Dystonia       Date:  2022-05-16

7.  The environmental epidemiology of primary dystonia.

Authors:  Giovanni Defazio; Angelo F Gigante
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2013-05-03

8.  In vivo confocal microscopy of meibomian glands in primary blepharospasm: A prospective case-control study in a Chinese population.

Authors:  Tong Lin; Lan Gong
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.